Ruxolitinib Prevents Pulmonary Function Decline Due to CLAD-BOS in an Adolescent Lung Transplant Recipient

Introduction: Ruxolitinib, an oral Janus-associated kinase 1 and 2 inhibitor, is approved for treatment of chronic graft versus host disease (cGVHD) in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Notably, ruxolitinib has shown promise as a therapy for bronchiolitis obliterans syndrome (BOS) after HSCT leading to improvement in pulmonary function. However, it has not been reported for treatment of BOS phenotype chronic lung allograft dysfunction (CLAD) after lung transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research